Cite

HARVARD Citation

    Goldstein, I. et al. (2020). Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases. Neuro-oncology advances. 2 (1), p. . [Online]. 
  
Back to record